Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Average Rating of “Hold” from Brokerages

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have been given an average recommendation of “Hold” by the five brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $27.8333.

A number of brokerages have weighed in on KMTS. The Goldman Sachs Group decreased their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research note on Wednesday. BTIG Research upped their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday. Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday.

Insider Buying and Selling at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00. Following the transaction, the insider owned 395,467 shares in the company, valued at $8,229,668.27. This trade represents a 3.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 3.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its position in shares of Kestra Medical Technologies by 137.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after purchasing an additional 2,529,851 shares during the period. Brown Advisory Inc. raised its position in shares of Kestra Medical Technologies by 34.1% during the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after purchasing an additional 428,996 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Kestra Medical Technologies by 13.7% in the 3rd quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after buying an additional 179,885 shares in the last quarter. Eventide Asset Management LLC lifted its stake in Kestra Medical Technologies by 5.4% in the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after buying an additional 65,288 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Kestra Medical Technologies by 180.8% in the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after buying an additional 612,343 shares during the last quarter.

Kestra Medical Technologies Price Performance

NASDAQ:KMTS opened at $24.42 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 7.32. The company has a 50 day moving average price of $22.28 and a 200-day moving average price of $22.72. Kestra Medical Technologies has a 1-year low of $14.10 and a 1-year high of $30.00. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -10.09 and a beta of 0.47.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The firm had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. Equities research analysts forecast that Kestra Medical Technologies will post -2.3 EPS for the current year.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.